WO2021207433A3 - Épitopes d'anticorps neutralisant le sars-cov-2 - Google Patents

Épitopes d'anticorps neutralisant le sars-cov-2 Download PDF

Info

Publication number
WO2021207433A3
WO2021207433A3 PCT/US2021/026286 US2021026286W WO2021207433A3 WO 2021207433 A3 WO2021207433 A3 WO 2021207433A3 US 2021026286 W US2021026286 W US 2021026286W WO 2021207433 A3 WO2021207433 A3 WO 2021207433A3
Authority
WO
WIPO (PCT)
Prior art keywords
cov
sars
epitopes
neutralizing antibodies
antibodies
Prior art date
Application number
PCT/US2021/026286
Other languages
English (en)
Other versions
WO2021207433A2 (fr
Inventor
Yifan Cheng
Daniel ASARNOW
Charles CRAIK
Aashish MANGLIK
Markus Bohn
Cheng-I Wang
Yuanyu HU
Bei Wang
Original Assignee
The Regents Of The University Of California
Agency For Science, Technology And Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of California, Agency For Science, Technology And Research filed Critical The Regents Of The University Of California
Publication of WO2021207433A2 publication Critical patent/WO2021207433A2/fr
Publication of WO2021207433A3 publication Critical patent/WO2021207433A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne de nouveaux anticorps anti-Spike du SARS-CoV-2, des compositions pharmaceutiques comprenant de tels anticorps, et des méthodes thérapeutiques d'utilisation de tels anticorps et compositions pharmaceutiques.
PCT/US2021/026286 2020-04-07 2021-04-07 Épitopes d'anticorps neutralisant le sars-cov-2 WO2021207433A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SG10202003204P 2020-04-07
SG10202003204P 2020-04-07
SG10202004828Q 2020-05-22
SG10202004828Q 2020-05-22

Publications (2)

Publication Number Publication Date
WO2021207433A2 WO2021207433A2 (fr) 2021-10-14
WO2021207433A3 true WO2021207433A3 (fr) 2021-11-25

Family

ID=78024068

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/SG2021/050195 WO2021206636A1 (fr) 2020-04-07 2021-04-07 Protéine de liaison à l'antigène dirigée contre sars-cov-2
PCT/US2021/026286 WO2021207433A2 (fr) 2020-04-07 2021-04-07 Épitopes d'anticorps neutralisant le sars-cov-2

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/SG2021/050195 WO2021206636A1 (fr) 2020-04-07 2021-04-07 Protéine de liaison à l'antigène dirigée contre sars-cov-2

Country Status (1)

Country Link
WO (2) WO2021206636A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202241942A (zh) * 2020-12-21 2022-11-01 日商中外製藥股份有限公司 Ｓａｒｓ－ｃｏｖ－２結合分子及其用途
CN113999301B (zh) * 2021-12-07 2023-07-28 江苏中新医药有限公司 抗SARS-CoV-2(COVID-19)S蛋白RBD单克隆抗体
CN114213531B (zh) * 2021-12-07 2023-04-25 中国人民解放军军事科学院军事医学研究院 抗新型冠状病毒中和抗体、其抗原结合片段及其应用
WO2024068777A1 (fr) 2022-09-28 2024-04-04 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Protéines ace2 modifiées présentant une activité améliorée contre le sars-cov-2

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007044695A2 (fr) * 2005-10-07 2007-04-19 Dana-Farber Cancer Institute Anticorps diriges contre le sras-cov et procedes d'utilisation de ceux-ci
WO2010032059A2 (fr) * 2008-09-19 2010-03-25 Medimmune Llc Agents de liaison ciblés dirigés sur cd105 et leurs utilisations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007044695A2 (fr) * 2005-10-07 2007-04-19 Dana-Farber Cancer Institute Anticorps diriges contre le sras-cov et procedes d'utilisation de ceux-ci
WO2010032059A2 (fr) * 2008-09-19 2010-03-25 Medimmune Llc Agents de liaison ciblés dirigés sur cd105 et leurs utilisations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CORMAN ET AL.: "Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR", EURO SURVEILL., vol. 25, no. 3, 23 January 2020 (2020-01-23), pages 23 - 30, XP055695049, DOI: 10.2807/1560-7917.ES.2020.25.3.2000045 *

Also Published As

Publication number Publication date
WO2021206636A1 (fr) 2021-10-14
WO2021207433A2 (fr) 2021-10-14

Similar Documents

Publication Publication Date Title
WO2021207433A3 (fr) Épitopes d'anticorps neutralisant le sars-cov-2
WO2017106346A3 (fr) Anticorps neutralisants le virus de l'immunodéficience humaine
PH12019501824A1 (en) Anti-gprc5d antibody and molecule comprising the antibody
WO2021222935A3 (fr) Anticorps anti-sras-cov-2 neutralisants et leurs procédés d'utilisation
WO2020014460A8 (fr) INHIBITEURS DE TGFβ1 SÉLECTIFS SELON L'ISOFORME À AFFINITÉ ÉLEVÉE
WO2018170351A8 (fr) Anticorps anti-phf-tau et leurs utilisations
CA3149406A1 (fr) Nouveaux anticorps anti-cldn18.2
WO2021183839A3 (fr) Nouveaux anticorps anti-lilrb4 et produits dérivés
WO2020014473A8 (fr) INHIBITEURS DE TGFβ1 ET LEUR UTILISATION
MX2022014896A (es) Anticuerpos anti-cldn18.2 y usos para diagnostico de los mismos.
WO2017214170A3 (fr) Anticorps baff-r et utilisations de ceux-ci
ZA202202363B (en) Antibodies against ilt2 and use thereof
WO2020157222A8 (fr) Toxines apxia, apxiia et apxiiia inactivées
MX2020009522A (es) Anticuerpos anti-folato del receptor 1 y usos de los mismos.
MX2023004869A (es) Anticuerpos contra sars-cov-2 y usos de los mismos.
WO2021118930A3 (fr) Formulations d'anticorps anti-pd-l1
WO2018183631A8 (fr) Nouvelles formulations pharmaceutiques contenant de l'indirubine et des dérivés de celui-ci et procédés de fabrication et d'utilisation de celles-ci
WO2022032073A3 (fr) Modulateurs de trpml
MX2023008423A (es) Anticuerpos anti-gremlin1 novedosos.
WO2022034524A3 (fr) Anticorps contre ilt2 et leur utilisation
MX2022007959A (es) Nuevos anticuerpos anti-fgfr2b.
MX2024007966A (es) Anticuerpos anti-tslp novedosos.
WO2021024133A3 (fr) Compositions biopharmaceutiques et procédés associés
WO2020180712A8 (fr) Anticorps anti-tnfr2 et leurs utilisations
MX2022015966A (es) Anticuerpos y metodos para tratar enfermedades asociadas a claudina.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21784809

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21784809

Country of ref document: EP

Kind code of ref document: A2